Last reviewed · How we verify
Intec Pharma Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
4 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo -AP-CD/LD | Placebo -AP-CD/LD | phase 3 | ||||
| Placebo- Sinemet | Placebo- Sinemet | phase 3 | Dopamine agonist | Dopamine receptors | Neurology | |
| Accordion Pill™ Carbidopa/Levodopa | Accordion Pill™ Carbidopa/Levodopa | phase 3 | Dopamine precursor with peripheral decarboxylase inhibitor | Aromatic L-amino acid decarboxylase (carbidopa); dopamine pathway (levodopa) | Neurology |
Therapeutic area mix
- Neurology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Axxonis Pharma AG · 1 shared drug class
- Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
- Beth Israel Deaconess Medical Center · 1 shared drug class
- Bial - Portela C S.A. · 1 shared drug class
- Britannia Pharmaceuticals Ltd. · 1 shared drug class
- Desitin Arzneimittel GmbH · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Intec Pharma Ltd.:
- Intec Pharma Ltd. pipeline updates — RSS
- Intec Pharma Ltd. pipeline updates — Atom
- Intec Pharma Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Intec Pharma Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/intec-pharma-ltd. Accessed 2026-05-14.